

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2995272

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CASEY KOPCZYNSKI	08/21/2014
CHENG-WEN LIN	08/21/2014
JILL MARIE STURTIVANT	08/21/2014
MITCHELL A. DELONG	08/21/2014
RECEIVING PARTY DATA	
Name:	AERIE PHARMACEUTICALS, INC.
Street Address:	7020 KIT CREEK ROAD, SUITE 270
Internal Address:	P.O. BOX 12320
City:	RESEARCH TRIANGLE PARK
State/Country:	NORTH CAROLINA
Postal Code:	27709
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14213961
CORRESPONDENCE DATA	
Fax Number:	(414)277-0656
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(414)271-6560
Email:	dahauser@michaelbest.com
Correspondent Name:	MICHAEL BEST & FRIEDRICH LLP
Address Line 1:	100 EAST WISCONSIN AVENUE
Address Line 2:	SUITE 3300
Address Line 4:	MILWAUKEE, WISCONSIN 53202-4108
ATTORNEY DOCKET NUMBER:	017425-9049-US02
NAME OF SUBMITTER:	CHARLENE L. YAGER
SIGNATURE:	/charlene l yager/
DATE SIGNED:	08/25/2014
Total Attachments: 2	
source=15556387_017425-9049-US02_As_Filed_Assignment#page1.tif	

ASSIGNMENT

Pursuant to our obligation to Aerie Pharmaceuticals, Inc. (hereinafter referred to as "Assignee"), a Delaware corporation having its principal place of business at:

7020 Kit Creek Road, Suite 270
P.O. Box 12320
Research Triangle Park, NC 27709

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we:

Casey Kopczynski
106 Glenhaven Drive
Chapel Hill, NC 27516

Cheng-Wen Lin
9211 Calabria Drive, Unit 102
Raleigh, NC 27617

Jill Marie Sturdivant
3930 Crawford Dairy Road
Chapel Hill, NC 27516

Mitchell A. deLong
2224 Pathway Drive
Chapel Hill, NC 27516

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest

(1) in and to inventions described in a patent application titled "COMBINATION THERAPY" for which we filed United States Patent Application No. 14/213,961 (Atty. File No. 017425-9049-US02) (hereinafter the "U.S. utility patent application") which application claims the benefit of United States Provisional Patent Application No. 61/787,883, filed March 15, 2013 (hereinafter the "U.S. provisional patent application") (Atty. File No. 017425-9049-US00);

(2) in and to the U.S. utility patent application, and the U.S. provisional patent application, in and to all other patent applications (including divisional, continuation, continuation-in-part, 35 U.S.C. §111(b) provisional, 35 U.S.C. §111(a), and reissue applications) based upon said inventions, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;


(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the U.S. utility patent application and the U.S. provisional patent application, and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on either or both of the U.S. utility patent application and the U.S. provisional patent application.


We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent or patents to Assignee.


8/21/2014
Date


Casey Kocczynski


8/21/2014
Date


Cheng-Wen Lin

8/21/2014
Date


Jill Marie Sturdivant

Aug 21, 2014
Date


Mitchell A. deLong